The effect of growth hormone addition protocols to poor ovarian responders in in vitro fertilization cycles

被引:3
作者
Bender, R. A. [1 ,2 ]
Ozcan, C. [3 ]
Aslancan, R. [4 ]
Akar, B. [5 ]
Caliskan, E. [6 ]
机构
[1] Biruni Univ, Dept Obstet & Gynecol, Sch Med, Istanbul, Turkey
[2] Medicana Int Hosp, Dept Obstet & Gynecol, Istanbul, Turkey
[3] Hlth Sci Univ Derince Training, Res Hosp, Dept Obstet & Gynecol, Kocaeli, Turkey
[4] Basaksehir Cam & Sakura City Hosp, Dept Obstet & Gynecol, Istanbul, Turkey
[5] Private Kocaeli Hosp, Dept Obstet & Gynecol, Kocaeli, Turkey
[6] Okan Univ, Dept Obstet & Gynecol, Sch Med, Istanbul, Turkey
关键词
Growth hormone; Poor ovarian response; Poor re-sponder; Controlled ovarian stimulation; In vitro fertil-ization; GNRH-AGONIST; ADJUVANT TREATMENT; STIMULATION; STRATEGIES; IVF;
D O I
10.26355/eurrev_202208_29420
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: In vitro fertilization failure (IVF) is high in women with poor ovarian response or non-responder. For this reason, the addition of adjuvant treatments to IVF protocols has come to the fore. We assessed to investi-gate the effects of adjuvant GH therapy initiated in the mid-luteal phase on IVF success in poor ovarian response or non-responder women. PATIENTS AND METHODS: A retrospective study was performed in 93 poor ovarian response or non-responder women from a single center. GH treatment was added (GH-plus group) in the mid-luteal phase of the previous menstrual cycle to 47 of the women who underwent con-trolled ovarian stimulation with the flexible antagonist protocol. 46 women, as another group, were applied to a flexible antagonist-only protocol (GH-free group). The IVF outcome results were evaluated and compared within the groups. RESULTS: The number of retrieved oocytes was statistically significantly higher in the GH-plus group (2.28 +/- 1.975) than in the GH-free group (1.24 +/- 1.728) (p=0.01). Although statistically in-significant (p=0.55), the clinical pregnancy rate was higher in the GH-plus group [(8/47), 17%] than in the GH-free group [(5/46, 11%]. The cancellation rate was statistically significantly higher in the GH-free group (65.2%) than in the GH-plus group (44.7%) (p=0.04). No oocyte retrieved cycle rate was higher in the GH-free group (56%) than in the GH-plus group (25%) (p=0.002). CONCLUSIONS: Adjuvant GH therapy administration to IVF protocol in the mid-luteal phase gives poor ovarian response or non-responder women a chance to have a baby.
引用
收藏
页码:5503 / 5508
页数:6
相关论文
共 24 条
  • [1] INSULIN-LIKE GROWTH-FACTORS AS INTRAOVARIAN REGULATORS OF GRANULOSA-CELL GROWTH AND FUNCTION
    ADASHI, EY
    RESNICK, CE
    DERCOLE, AJ
    SVOBODA, ME
    VANWYK, JJ
    [J]. ENDOCRINE REVIEWS, 1985, 6 (03) : 400 - 420
  • [2] Age-related normograms of serum antimullerian hormone levels in a population of infertile women: a multicenter study
    Almog, Benny
    Shehata, Fady
    Suissa, Sami
    Holzer, Hananel
    Shalom-Paz, Einat
    La Marca, Antonio
    Muttukrishna, Shanthi
    Blazar, Andrew
    Hackett, Richard
    Nelson, Scott M.
    Cunha-Filho, Joao Sabino
    Eldar-Geva, Talia
    Margalioth, Ehud J.
    Raine-Fenning, Nick
    Jayaprakasan, Kannamannadiar
    McIlveen, Myvanwy
    Wunder, Dorothea
    Freour, Thomas
    Nardo, Luciano G.
    Balasch, Juan
    Penarrubia, Joana
    Smeenk, Jesper
    Gnoth, Christian
    Godehardt, Erhard
    Lee, Tsung-Hsien
    Lee, Maw-Sheng
    Levin, Ishai
    Gamzu, Ronni
    Tulandi, Togas
    [J]. FERTILITY AND STERILITY, 2011, 95 (07) : 2359 - U280
  • [3] Age-related normogram for antral follicle count: McGill reference guide
    Almog, Benny
    Shehata, Fady
    Shalom-Paz, Einat
    Tan, Seang Lin
    Tulandi, Togas
    [J]. FERTILITY AND STERILITY, 2011, 95 (02) : 663 - 666
  • [4] ESHRE guideline:oval n s simulation for IVF/ICSI
    Bosch, Ernesto
    Broer, Simone
    Griesinger, Georg
    Grynberg, Michael
    Humaidan, Peter
    Kolibianakis, Estratios
    Kunicki, Michal
    La Marca, Antonio
    Lainas, George
    Le Clef, Nathalie
    Massin, Nathalie
    Mastenbroek, Sebastiaan
    Polyzos, Nikolaos
    Sunkara, Sesh Kamal
    Timeva, Tanya
    Toyli, Mira
    Urbancsek, Janos
    Vermeulen, Nathalie
    Broekmans, Frank
    [J]. HUMAN REPRODUCTION OPEN, 2020, 2020 (02)
  • [5] Which is the best IVF/ICSI protocol to be used in poor responders receiving growth hormone as an adjuvant treatment? A prospective randomized trial
    Dakhly, Dina M. R.
    Bayoumi, Yomna A.
    Allah, Sherine H. Gad
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2016, 32 (02) : 116 - 119
  • [6] Growth hormone for in vitro fertilization
    Duffy, James M. N.
    Ahmad, Gaity
    Mohiyiddeen, Lamiya
    Nardo, Luciano G.
    Watson, Andrew
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (01):
  • [7] Growth Hormone Supplementation in the Luteal Phase Before Microdose GnRH Agonist Flare Protocol for In Vitro Fertilization
    Dunne, Caitlin
    Seethram, Ken
    Roberts, Jeffrey
    [J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2015, 37 (09) : 810 - 815
  • [8] Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poor responders undergoing IVF
    Fasouliotis, SJ
    Laufer, N
    Sabbagh-Ehrlich, S
    Lewin, A
    Hurwitz, A
    Simon, A
    [J]. JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2003, 20 (11) : 455 - 460
  • [9] ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria
    Ferraretti, A. P.
    La Marca, A.
    Fauser, B. C. J. M.
    Tarlatzis, B.
    Nargund, G.
    Gianaroli, L.
    [J]. HUMAN REPRODUCTION, 2011, 26 (07) : 1616 - 1624
  • [10] Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481